
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics Inc. has achieved a significant milestone with a $5 million payment from Roche, reflecting advances in manufacturing and clinical progress for its OpRegen therapy, targeting geographic atrophy associated with age-related macular degeneration. The promising early data on OpRegen suggests potential for vision reversal, which may differentiate it from currently approved treatments that primarily slow disease progression. Additionally, the ongoing advancements in Lineage’s ReSonance program, alongside the efficient allocation of resources to secure intellectual property, indicate a strong foundation for future growth across multiple therapeutic indications.
Bears say
Lineage Cell Therapeutics faces significant financial risks due to the potential for failed or inconclusive clinical trials, which could hinder the progress of its drug candidates through development. Additionally, the company may encounter challenges in securing adequate funding necessary for advancing its pipeline, exacerbating uncertainties around its financial stability. The inherent risks associated with the regenerative medicine sector further compound the negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares